This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET/CT.
Diagnosed with primary classical Hodgkin lymphoma (HL) based on histopathology.
Stage I-II .
At least one measurable target lesion（Lugano 2014）.
Age 18 years or older (including 18 years) to 45 years (recent fertility requirements and concern about chemotherapy side effects), or age >60 years (older patients who are frail and unwilling to undergo chemotherapy), male or female.
Hodgkin's lymphoma with nodular lymphocyte predominant type.
Patients who are scheduled to undergo subsequent autologous stem cell transplantation.
Contraindications to radiotherapy.
With central nervous system (meningeal or parenchymal) involvement.
Sun Yat-sen University
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Collaborator